Implementing cancer genetic screening is critical as individuals who carry a BRCA1/2 mutation have significantly increased lifetime risks for breast (50%–80%) and ovarian cancer (10%–40%), and individuals with LS have an increased lifetime risk of developing colorectal cancer (22%–74%), endometrial cancer (15%–71%), and ovarian cancer (4%–20%).22, 23, 24. This evidence concerns the gene BRCA1 and ovarian carcinoma.